NewGenIvf Group Limited
NIVF · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5,433 | $5,136 | $5,944 | $4,118 |
| % Growth | 5.8% | -13.6% | 44.3% | – |
| Cost of Goods Sold | $3,606 | $3,454 | $4,406 | $3,093 |
| Gross Profit | $1,827 | $1,682 | $1,538 | $1,025 |
| % Margin | 33.6% | 32.7% | 25.9% | 24.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $2,781 | $1,622 | $1,103 | $801 |
| SG&A Expenses | $2,987 | $1,640 | $1,139 | $826 |
| Sales & Mktg Exp. | $206 | $18 | $36 | $25 |
| Other Operating Expenses | -$186 | $0 | $0 | $0 |
| Operating Expenses | $2,801 | $1,640 | $1,139 | $826 |
| Operating Income | -$1,160 | $42 | -$505 | $199 |
| % Margin | -21.4% | 0.8% | -8.5% | 4.8% |
| Other Income/Exp. Net | $200 | $66 | $1,006 | -$43 |
| Pre-Tax Income | -$961 | $108 | $501 | $156 |
| Tax Expense | -$487 | $0 | $208 | $295 |
| Net Income | -$525 | $130 | $459 | -$1 |
| % Margin | -9.7% | 2.5% | 7.7% | -0% |
| EPS | -115.25 | 64.25 | 323 | -0.025 |
| % Growth | -279.4% | -80.1% | 1,292,100% | – |
| EPS Diluted | -115.25 | 64.25 | 323 | -0.025 |
| Weighted Avg Shares Out | 114 | 51 | 51 | 51 |
| Weighted Avg Shares Out Dil | 114 | 51 | 51 | 51 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $1 | $0 | $0 |
| Interest Expense | $779 | $46 | $78 | $88 |
| Depreciation & Amortization | $206 | $230 | $304 | $343 |
| EBITDA | $24 | $384 | $726 | $587 |
| % Margin | 0.4% | 7.5% | 12.2% | 14.3% |